- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03089697
Phase IIa Clinical Study of N-Rephasin® SAL200
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIa Clinical Study to Evaluate Safety and to Explore Efficacy of N-Rephasin® SAL200, in Patients With Persistent Staphylococcus Aureus Bacteremia
Study Overview
Status
Intervention / Treatment
Detailed Description
Subjects:
Patients with persistent Staphylococcus aureus bacteremia for more than 48 hours from the beginning of antibiotics treatment to which Staphylococcus aureus is susceptible.
Study Method:
- Selection of patients with persistent S.aureus bacteremia for more than 48 hours even after application of the standard treatment for S. aureus bacteremia
- Randomization according to the trial institutions
- The control group receives a single intravenous dose of the placebo in addition to the standard treatment for persistent Staphylococcus aureus bacteremia
- The study group receives a single intravenous dose of the N-Rephasin® SAL200 (3 mg/kg) in addition to the standard treatment for persistent Staphylococcus aureus bacteremia
- A blood culture is performed 18 hours (±6 hours) after the administration of N-Rephasin® SAL200
- Blood cultures continue to be performed every 24 hours (±6 hours) or 48 hours (±6 hours) after the previous blood culture, until two consecutive results of 'no growth (negative conversion)' are obtained
- Adverse events are monitored at the time of the first blood culture following the administration of N-Rephasin® SAL200 or placebo, and at the subsequent intervals of 24 hours or 48 hours
Statistical Analysis:
Primary endpoints
- Safety analysis is conducted in the Safety group. A distribution table of patients who experience at least one adverse event (incidence), and distribution tables of the relationship of the reported adverse events with the investigational product (distribution tables for severity and the relationship with the drug) are presented with respect to the groups (study group, control group), to determine safety of the investigational product.
- The results of the laboratory tests, anaphylaxis test, inflammatory cytokine test and vital signs at baseline and the last visit are summarized as mean values and standard deviations, to determine the change before and after the treatment within each group.
- Categorical data are divided into normal and abnormal, and summarized as the frequency and percentage to determine the difference before and after treatment within each group.
Secondary endpoints
- Proportion of patients who are negative for bacterial growth in the first blood culture after administration of the investigational drug. The descriptive statistics for the proportion of patients who are negative for bacterial growth in the first blood culture (the rate of no growth) after the first treatment are presented by treatment group. Whether the rate of no growth is superior in the study group compared to the control group, is evaluated by a descriptive statistical method.
- Proportion of patients who die due to S. aureus bacteremia by Day14 after the incidence of bacteremia. The descriptive statistics for the proportion of patients who die due to S. aureus bacteremia by Day14 are presented by treatment group and evaluated.
- Proportion of treatment failure for S. aureus bacteremia by Day 14 (if two consecutive results of 'no growth' are not achieved in the blood cultures which are performed until Day 14. The descriptive statistics for the proportion of treatment failure for S. aureus bacteremia by Day 14 are presented and evaluated.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with MSSA/MRSA bacteremia who are confirmed to have more than a pair of Gram positive bacteria in a blood culture conducted at 48~96 hours after the start of antibiotic treatment to which S. aureus is susceptible.
- Males or females aged 19 years or older
- Those who understand the explanatory notes for subjects, and sign the informed consent.
Exclusion Criteria:
- Those who do not receive appropriate antibiotics within 48 hours after the occurrence of bacteremia (the time point of reporting it to the department of laboratory medicine)
- The Gram positive strain, identified in a blood culture conducted at 48~96 hours after the start of antibiotic treatment to which S. aureus is susceptible, is not the same strain of S. aureus which was cultured when the definite diagnosis of S. aureus bacteremia was made
- Those who pass 48 hours after confirmation of persistent S. aureus bacteremia through a blood culture conducted at 48~96 hours after the start of antibiotic treatment to which S. aureus is susceptible
Those who have symptoms of septic shock at the time of acquisition of the consent form
- Systolic blood pressure lower than 90 mmHg, or blood pressure lower than usual by more than 40 mmHg, in spite of the application of appropriate fluid therapy
- Requirement of hypertensor to maintain the systolic blood pressure at 90 mmHg or higher
- Those who were infected with mixed bacterial species
- Those who are hypersensitive to N-Rephasin® SAL200, who have a clinically significant hypersensitivity to it, or a past history there of
- Pregnant or lactating women and women of child-bearing potential (who do not agree to take appropriate contraceptive measures during the trial period)
- Those who participated in other clinical trial within 30 days prior to enrollment
- Patients with any conditions that may interfere with study participation or accurate evaluation on investigator's judgment
- Those who may die within 72 hours due to other serious complications (e.g., cerebral infarction, etc.), as per the investigator's judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: N-Rephasin® SAL200
To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
|
A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
|
Placebo Comparator: Placebo
To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
|
A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Endpoints - Summary of Treatment-emergent Adverse Events (Safety Set)
Time Frame: up to 4 Week ± 5 Days
|
The safety analysis was conducted based on the data of all AEs, physical examinations, clinical laboratory tests, and vital signs (blood pressure, pulse rate, body temperature, and respiratory rate) collected from the subjects. All subjects who enrolled in this study (13 subjects in the placebo group and 12 subjects in the N RephasinⓇ SAL200 group) were defined as the Safety Set and included in the analysis. |
up to 4 Week ± 5 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Endpoints 1
Time Frame: by day 14
|
Number of Participants With Negative Result in the First Blood Culture
|
by day 14
|
Efficacy Endpoint 2
Time Frame: by day 14
|
The Proportion (Percentage) of Subjects who Died of Staphylococcus aureus Bacteremia Within 14 Days of Bacteremia Diagnosis
|
by day 14
|
Efficacy Endpoint 3
Time Frame: by day 14
|
Proportion (Percentage) of Treatment Failure Against Staphylococcus aureus Bacteremia by Day 14
|
by day 14
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hong-Bin Kim, M.D, PhD, Seoul National University Bundang Hospital
- Principal Investigator: Wan Beom Park, M.D, PhD, Seoul National University Hospital
Publications and helpful links
General Publications
- Kundsin RB. Documentation of airborne infection during surgery. Ann N Y Acad Sci. 1980;353:255-61. doi: 10.1111/j.1749-6632.1980.tb18928.x. No abstract available.
- Etienne J, Fleurette J, Ninet JF, Favet P, Gruer LD. Staphylococcal endocarditis after dental extraction. Lancet. 1986 Aug 30;2(8505):511-2. doi: 10.1016/s0140-6736(86)90377-6. No abstract available.
- Lamy B, Dargere S, Arendrup MC, Parienti JJ, Tattevin P. How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art. Front Microbiol. 2016 May 12;7:697. doi: 10.3389/fmicb.2016.00697. eCollection 2016.
- van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11.
Helpful Links
- Etiene J, Fleurette J, Ninet JF, Favet P, Gruer LD. Staphylococcus endocarditis after dental extraction. Lancet. 1986;2:511-512
- Frency J, Brun Y, Bes M, Meugnier H, Grimont F, Grimon PAD, Newi C, Fleurette J. Staphylococcus lugdunensis sp. and Staphylococcus schleiferi sp. novel two species from human clinical specimens. Int Syst Bacteriol. 1998;38:168-172
- Seung-Ho Han et al., Monitoring of Methicillin-Resistant Staphylococcus aureus in Nasal Swabs Obtained fron Dental Clinic Healthcare Providers and Medical Environments Nurses. Int J Oral Biology. 2010;35:7-12
- Hyuk Min Lee, Dong Eun Yong, Kyungwon Lee., Antimicrobial Resistance of Clinically Important Bacteria Isolated from 12 Hospitals in Korea in 2004 . Korean Journal of Clinical Microbiology 2005;8(1):66-73
- Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007;35(10 SUPPL. 2):S165-93.
- Woo J-H, Song J-H, Cheong H-S, Lee E-K, Chae S-M, Kim N-J. Analysis of Economic Outcomes of Methicillin-Resistant Staphylococcus Aureus(MRSA) Bacteremia Using Retrospective Case-Control Study. Korean J Clin Pharm 2007;17(2):59-64.
- Lee, H, Yong, D, Lee, K, Hong, S, Kim, E, Jung, S, Park, Y, Choi, T, Eo, Y, Shin, J et al. Antimicrobial Resistance of Clinically Important Bacteria Isolated from 12 Hospitals in Korea in 2004. Korean J Clinical Microbiology 2005;8(1):66-73
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ITB-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anti-Bacterial Agents
-
Chiang Mai UniversityCompletedAnti-Bacterial Agents
-
Washington University School of MedicineCompleted
-
Eskisehir Osmangazi UniversityTC Erciyes UniversityCompleted
-
Intermountain Health Care, Inc.CompletedAntibiotic Stewardship | Inappropriate Prescribing | Anti-Bacterial Agents
-
Children's Mercy Hospital Kansas CityPatient-Centered Outcomes Research Institute; Washington University School... and other collaboratorsCompletedCommunication | Personal Satisfaction | Decision Making | Anti-Bacterial AgentsUnited States
-
Asan Medical CenterSeoul Business AgencyRecruitingPharmacokinetics | General Surgery | Anti-bacterial AgentsKorea, Republic of
-
Stony Brook UniversityThe Plastic Surgery FoundationCompletedBreast Implantation | Bacterial Infection | Anti-infective AgentsUnited States
-
CONRADUnited States Agency for International Development (USAID); Agility Clinical...CompletedContraceptive Usage | Anti-Infective Agents | Anti-Retroviral AgentsDominican Republic, United States
-
University of Missouri-ColumbiaRecruitingInfection, Bacterial | Anti-bacterial Agents | Hand Injuries | Arm Injury | Cat BiteUnited States
-
Daniela Francescato VeigaRecruitingWound Infection | Anti-bacterial Agents | Mammaplasty | Prophylaxis | Plastic SurgeryBrazil
Clinical Trials on N-Rephasin® SAL200
-
Intron Biotechnology, Inc.CompletedHealthy Volunteers | Anti-Bacterial Agents | Methicillin-Resistant Staphylococcus AureusKorea, Republic of
-
Intron Biotechnology, Inc.CompletedHealthy Volunteers | Anti-Bacterial Agents | Methicillin-Resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionKorea, Republic of
-
Bionorica SECompletedUrinary Tract InfectionUkraine
-
Hospital Vall d'HebronBayer Hispania, S.LCompletedFunctional Dyspepsia | Irritable Bowel SyndromeSpain
-
Liaquat University of Medical & Health SciencesRecruiting
-
WockhardtTerminatedType I DiabetesUnited States, India
-
Istituto Clinico HumanitasCompletedInflammation | Hypertension | Parkinson's Disease | Autonomic NeuropathyItaly
-
Bionorica SECompletedUrinary Tract InfectionGermany
-
GuerbetCompletedRenal InsufficiencyFrance, Belgium, Spain, Italy
-
GuerbetCompleted